lenalidomide/pharmazac caps 5mg/cap
ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 5mg/cap - lenalidomide 5mg - lenalidomide
vesicare f.c.tab 5mg/tab
astellas pharmaceuticals aebe Αγησιλάου 6-8, 151 23 Μαρούσι 210.8189900 - solifenacin succinate - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 5mg/tab - solifenacin succinate 5mg - solifenacin
vesicare f.c.tab 10mg/tab
astellas pharmaceuticals aebe Αγησιλάου 6-8, 151 23 Μαρούσι 210.8189900 - solifenacin succinate - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 10mg/tab - solifenacin succinate 10mg - solifenacin
vesicare oral.susp 1mg/1ml
astellas pharmaceuticals aebe Αγησιλάου 6-8, 151 23 Μαρούσι 210.8189900 - solifenacin succinate - oral.susp (ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 1mg/1ml - solifenacin succinate 1mg - solifenacin
vesicare 5mg film coated tablets
astellas pharmaceuticals a.e.b.e. (0000010363) agisilaou 6-8, athens, tr 15123 - solifenacin succinate - film coated tablets - 5mg - solifenacin succinate (8000002101) 5mg - solifenacin
vesicare 10mg film coated tablets
astellas pharmaceuticals a.e.b.e. (0000010363) agisilaou 6-8, athens, tr 15123 - solifenacin succinate - film coated tablets - 10mg - solifenacin succinate (8000002101) 10mg - solifenacin
vesicare 1mg/ml oral suspension
astellas pharmaceuticals a.e.b.e. (0000010363) agisilaou 6-8, athens, tr 15123 - solifenacin succinate - oral suspension - 1mg/ml - solifenacin succinate (8000002101) 1mg - solifenacin
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - υδροχλωρική κλοπιδογρέλη - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Αντιθρομβωτικοί παράγοντες - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
vildagliptin pharmathen 50mg tablets
pharmathen s.a. (0000009374) 6 dervenakion str, pallini, attikis, 15351 - vildagliptin - tablets - 50mg - vildagliptin (8000003377) 50mg
deferasirox pharmathen 360mg film coated tablets
pharmathen s.a. (0000009374) 6 dervenakion str, pallini, attikis, 15351 - deferasirox - film coated tablets - 360mg - deferasirox (8000003150) 360mg